Danel (Adir Yeoshua) Ltd (DANE) Fair Value & Analysis

Healthcare · Il · Market cap 2.7B ILA

A solid business, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Our model range runs from 308.84 ILA (bear) to 514.73 ILA (bull), base 411.78 ILA. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 67/100 (solid quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.

How to read this chart

60‑month range 216.20 ILA – 730.83 ILA · fair‑value band 308.84 ILA – 514.73 ILA · the 453.70 ILA price screens above the 411.78 ILA fair value. Dashed = 300-day average. As of Jul 11, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Danel (Adir Yeoshua) Ltd (DANE) currently trades at 453.70 ILA, while our model-based Fair Value estimate is 411.78 ILA, implying the stock looks roughly 9.2% fairly valued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Danel (Adir Yeoshua) Ltd generated revenue of 2.9B ILA at a net margin of 4.3%. Revenue grew 3.7% year over year. It earns a return on equity of 28.4%. Net debt stands at 113M ILA. Fundamentals as of Jul 11, 2026

Our scenario range runs from 308.84 ILA (bear case) to 514.73 ILA (bull case); at 453.70 ILA, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -9%, DANE screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (516.09 ILA) versus Asset-Based (57.02 ILA). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Danel (Adir Yeoshua) Ltd provides human resources services in Israel. The company provides recruitment, placement, and employment services in the areas of finance, insurance, administration, senior management, high-tech, biotech, cleantech, as well as outsourcing project management services, technological employee employment services, and occupational and …

Full company description

Danel (Adir Yeoshua) Ltd provides human resources services in Israel. The company provides recruitment, placement, and employment services in the areas of finance, insurance, administration, senior management, high-tech, biotech, cleantech, as well as outsourcing project management services, technological employee employment services, and occupational and computerized diagnostic services; payroll services; and nursing and medical services to disabled seniors, ministry of defense beneficiaries, and others. It also manages and operates dormitories and hostels, schools, rehabilitation and therapeutic day centers; and provides Referrals to special schools for complex populations, such as multisystemic learning disabilities, moderate-low functioning autism, intellectual disabilities, mental/emotional difficulties, and behavioral disorders. In addition, the company provides medical services, including surgical activities in ophthalmology field. Danel (Adir Yeoshua) Ltd was incorporated in 1974 and is based in Ramat Gan, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Danel (Adir Yeoshua) Ltd reported revenue of 2.9B ILA in FY2025 versus 2.3B ILA in FY2021, a compound +6.1%/yr. Reported net income was 117M ILA in FY2025, compounding −9.5%/yr from FY2021.

Watch DANE: get an alert when its fair value changes →

Peer Group

Medical Care Facilities · 262 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.